Background: The role of implantable cardioverter defibrillator (ICD) in reducing mortality in patients with left ventricular assisted devices (LVADs) listed for heart transplant remains unclear. We therefore, sought to interrogate whether ICDs are associated with reduced mortality in patients with LVADs listed for heart transplantation.
Methods: We searched the United Network for Organ Sharing (UNOS) Registry for LVAD patients (age≥18years) with dilated cardiomyopathies listed for heart transplantation (2008-2015). The group was matched by propensity scores with respect to presence of ICD at listing. The primary end-point was waitlist mortality, while secondary endpoints were waitlist mortality, delisting, or cardiovascular cause-specific mortality in patients with and without ICD.
Results: A total of 1444 LVAD patients were included in this analysis (722 with ICD, 722 without ICD). No statistically-significant differences were present between the two groups in demographics, device type, listing status, or hemodynamics. The presence of an ICD was not associated with decreased wait-list mortality (Hazard Ratio 1.19 [0.75-1.88], p=0.46), waitlist mortality/delisting (Hazard Ratio 1.20 [0.86-1.67], p=0.28), or cardiovascular wait-list mortality (HR 1.24 [0.45-3.43], p=0.67) over a median of 5.6months. Only 7 deaths occurred due to arrhythmia/cardiac arrest (2 in the ICD group and 5 in the non-ICD group).
Conclusion: Presence of ICDs at listing in heart failure patients bridged to transplantation with durable LVADs is not associated with lower waitlist mortality, cardiovascular wait-list mortality or wait-list mortality or delisting; however, there were numerically fewer arrhythmic deaths in the ICD group. Additional prospective studies should be undertaken to confirm these findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2016.12.148 | DOI Listing |
BMC Womens Health
January 2025
School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Ovarian cancer is a leading cause of mortality worldwide. The third most prevalent gynecological cancer globally, following cervical and uterine cancer, and the third leading cause of cancer-related mortality among women in Sub-Saharan Africa, including Ethiopia. The time ovarian cancer patients have to wait between diagnosis and initiation of treatment are the indicators of quality in cancer care and influence patient outcomes.
View Article and Find Full Text PDFJ Clin Med
January 2025
Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
: High-volume online hemodiafiltration (OL-HDF) has proven to be the most efficient dialysis modality and to offer better clinical outcomes in patients on hemodialysis. Longer and more frequent dialysis sessions have demonstrated clinical and survival benefits. : A single-center observational study of the first one hundred patients on nocturnal every-other-day OL-HDF was conducted with the aim of reporting the experience with this treatment schedule and evaluating analytical and clinical outcomes as well as the patient and technique survival.
View Article and Find Full Text PDFPediatr Transplant
February 2025
Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
Purpose: In October 2018, the OPTN changed adult heart transplant (HT) allocation policy, increasing the number of adult candidates that had higher priority than pediatric candidates, potentially disadvantaging pediatric waitlist registrants.
Methods: To understand the impact of this policy change, we used SRTR data to identify 1469 pre-policy (7/2016-9/2018) and 2901 (10/2018-12/2022) post-policy pediatric (< 18 years) HT registrants. We quantified mortality and transplant risks using weighted cause-specific hazard models, and then using weighted competing risks regression.
Clin Transplant
January 2025
Department of Cardiovascular Medicine, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
Background: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.
Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.
Methods: This is a retrospective review of end-stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020.
Hepatol Commun
January 2025
Division of Transplant, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!